Marker Therapeutics Inc has a consensus price target of $1, established from looking at the 1 latest analyst ratings. The last 1 analyst ratings were released from Roth Capital on February 17, 2022. With an average price target of $1 between Roth Capital, there's an implied -75.99% downside for Marker Therapeutics Inc from these 1 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/17/2022 | MRKR | Buy Now | Marker Therapeutics | $4.17 | -75.99% | Roth Capital | Tony Butler | $30 → $10 | Downgrade | Buy → Neutral | Get Alert |
The latest price target for Marker Therapeutics (NASDAQ: MRKR) was reported by Roth Capital on February 17, 2022. The analyst firm set a price target for $1.00 expecting MRKR to fall to within 12 months (a possible -75.99% downside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for Marker Therapeutics (NASDAQ: MRKR) was provided by Roth Capital, and Marker Therapeutics downgraded their neutral rating.
There is no last upgrade for Marker Therapeutics.
The last downgrade for Marker Therapeutics Inc happened on February 17, 2022 when Roth Capital changed their price target from $3 to $1 for Marker Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marker Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marker Therapeutics was filed on February 17, 2022 so you should expect the next rating to be made available sometime around February 17, 2023.
While ratings are subjective and will change, the latest Marker Therapeutics (MRKR) rating was a downgraded with a price target of $3.00 to $1.00. The current price Marker Therapeutics (MRKR) is trading at is $4.17, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.